iconiifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Zydus Lifesciences gets USFDA approval for Esomeprazole Magnesium

8 Jun 2023 , 02:06 PM

Zydus Lifesciences Limited informed that the United States Food and Drug Administration (USFDA) has granted final approval for Esomeprazole Magnesium for Delayed-Release Oral Suspension, 20 mg, and 40 mg.

Esomeprazole is a medication used to treat stomach and esophageal problems (such as acid reflux and ulcers). It functions by reducing the amount of acid produced by your stomach. It alleviates symptoms like heartburn, difficulty swallowing, and coughing.

This medication aids in the healing of acid damage to the stomach and esophagus, the prevention of ulcers, and the prevention of Esophageal cancer.

Esomeprazole belongs to the proton pump inhibitor (PPI) class of drugs. The company will manufacture the product at the group’s formulation facility located in Moraiya, Ahmedabad (India).

In the United States, Esomeprazole Magnesium for Delayed-Release Oral Suspension, 20 mg, and 40 mg had annual sales of USD 42 million, as per IQVIA MAT April 2023.

Since the beginning of the filing process in FY 2003-04, the group has received 370 approvals and has filed over 442* ANDAs.

At around 1.55 PM, Zydus Lifesciences was trading 0.19% lower at Rs 514.10 against the previous close of Rs 515.10 on NSE.

For feedback and suggestions, write to us at editorial@iifl.com

explored-media

Related Tags

  • Pharma news
  • USFDA approval
  • Zydus
  • Zydus Lifesciences
  • Zydus Lifesciences news
  • Zydus Lifesciences Stock
  • Zydus Lifesciences Updates
sidebar mobile

BLOGS AND PERSONAL FINANCE

Images
28 Mar 2024   |   03:36 PM
Images
28 Mar 2024   |   03:01 PM
Images
28 Mar 2024   |   01:21 PM
Images
28 Mar 2024   |   01:02 PM
Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.